基础胰岛素联合GLP-1受体激动剂治疗2型糖尿病疗效和安全性分析

为了探讨基础胰岛素联合胰高糖素样肽-1(GLP-1)受体激动剂治疗2型糖尿病(T2DM)疗效和安全性,选取2017年1月至2019年1月该院T2DM患者200例,依据随机数字表分为A组和B组,每组100例,A组给予基础胰岛素治疗,B组在此基础上给予GLP-1受体激动剂(利司那肽)治疗,比较两组胰岛素功能[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能(HOMA-β)]、血糖控制[空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖基化血红蛋白(HbA1c)]、治疗疗效、不良反应。A组和B组治疗后FINS、HOMA-IR、FBG、2hPBG、HbA1c明显低于治疗前,B组治疗后FINS、HOMA-IR、FBG、2hPBG、HbA1c明显低于A组,A组和B组治疗后HOMA-β明显高于治疗前,B组治疗后HOMA-β明显高于A组,差异有统计学意义(P<0.05);B组治疗有效率明显高于A组,差异有统计学意义(P<0.05);A组和B组不良反应率比较,差异无统计学意义(P>0.05)。基础胰岛素联合GLP-1受体激动剂可有效改善T2DM患者胰岛素功能、血糖控制效果,有利于提高疗效,且安全性好,可供临床应用参考。

The Efficacy and Safety of Basic Insulin Combined with GLP-1 Receptor Agonist in the Treatment of Type 2 Diabetes Mellitus

To discuss the efficacy and safety of basic insulin combined with glucagon-like peptide-1(GLP-1)receptor agonist in the treatment of type 2 diabetes mellitus(T2DM),200 patients with T2DM in author's hospital from January 2017 to January 2019 were selected,they were divided into group A and group B according to the random number table.100 patients in each group.The group A were treated with basic insulin,the group B were treated with GLP-1 receptor agonist(lisinoptide)on the basis,the insulin function[fasting insulin(FINS),insulin resistance index(HOMA-IR),pancreatic beta cell function(HOMA-beta)],blood glucose control[fasting blood glucose(FBG),2 h postprandial blood glucose(2hPBG),glycosylated hemoglobin(HbA1c)],therapeutic efficacy and adverse reactions were compared between the two groups.The FINS,HOMA-IR,FBG,2hPBG and HbA1c in group A and group B after treatment were significantly lower than those before treatment,the FINS,HOMA-IR,FBG,2hPBG and HbA1c in group B after treatment were significantly lower than those in group A,the HOMA-beta in group A and group B after treatment were significantly higher than those before treatment,the HOMA-beta in group B after treatment was significantly higher than that in group A,the difference was statistically significant(P<0.05).The effective rate in group B was significantly higher than that in group A,the difference was statistically significant(P<0.05).There was no significant difference in adverse reactions between group A and group B(P>0.05).Basic insulin combined with GLP-1 receptor agonist can effectively improve insulin function and blood sugar control in patients with T2DM,which is helpful to improve the efficacy,and it is safety,it's worth for further clinical consult.